Comprehensive Psychiatry
Volume 46, Issue 6 , Pages 460-467 , November 2005

Cardiovascular disease in relation to weight in deceased persons with schizophrenia

  • Robert R. Conley

      Affiliations

    • Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    • ,
  • Joo-Cheol Shim

      Affiliations

    • Department of Psychiatry and Clinical Trials Center, Busan Park Hospital, Inje University, Busan, Korea
    • ,
  • Deanna L. Kelly

      Affiliations

    • Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    • Corresponding Author InformationCorresponding author. Maryland Psychiatric Research Center, Box 21347, Baltimore, MD 21228, USA. Tel.: +1 717 764 9260; fax: +1 410 402 6038.
    • ,
  • Stephanie Feldman

      Affiliations

    • Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    • ,
  • Yang Yu

      Affiliations

    • Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA
    • ,
  • Robert P. McMahon

      Affiliations

    • Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228, USA

References 

  1. National Center for Health Statistics. National Vital Statistics Report. Vol 49. No. 6. Web site at http://www.cdc.gov/nchs/data/nvsr/nvsr49/nvsr49_12.pdf[accessed Feb 11, 2004]
  2. Davidson M. Risk of cardiovascular disease and sudden death in schizophrenia. J Clin Psychiatry. 2002;63(Suppl 9):5–11
  3. Lesage AD, Trapani V, Tansella M. Excess mortality by natural causes of Italian schizophrenic patients. Eur Arch Psychiatry Neurol Sci. 1990;239(6):361–365
  4. Simpson JC, Tsuang MT. Mortality among patients with schizophrenia. Schizophr Bull. 1996;22(3):485–499
  5. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53
  6. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212–217
  7. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997;171:502–508
  8. Siris SG. Suicide and schizophrenia. J Psychopharmacol. 2001;15(2):127–135
  9. Casadebaig F, Philippe A. Mortality in schizophrenic patients. 3 Years follow-up of a cohort. Encephale. 1999;25(4):329–337
  10. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality. Br J Psychiatry. 2001;179:498–502
  11. Josiassen RC, Schindler B. Medical comorbidity and schizophrenia: editors' introduction. Schizophr Bull. 1996;22(3):411–412
  12. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry. 1999;60(Suppl 21):10–15
  13. Foulds J. The relationship between tobacco use and mental disorders. Curr Opin Psychiatry. 1999;12(3):303–306
  14. Holmberg SK, Kane C. Health and self-care practices of persons with schizophrenia. Psychiatr Serv. 1999;50(6):827–829
  15. Burggraf GW. Are psychotropic drugs at therapeutic levels a concern for cardiologists?. Can J Cardiol. 1997;13(1):75–80
  16. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46(3):273–281
  17. McGill HC, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002;105(23):2712–2718
  18. Schunkert H. Obesity and target organ damage: the heart. Int J Obes Relat Metab Disord. 2002;26(Suppl 4):S15–S20
  19. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60(4):215–220
  20. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry. 2001;46(6):549–555
  21. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res. 2002;55(3):277–284
  22. Horrobin DF. Schizophrenia as a prostaglandin deficiency disease. Lancet. 1977;1(8018):936–937
  23. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry. 1991;30(8):795–805
  24. Berger GE, Wood SJ, Pantelis C, Velakoulis D, Wellard RM, McGorry PD. Implications of lipid biology for the pathogenesis of schizophrenia. Aust N Z J Psychiatry. 2002;36(3):355–366
  25. Frankenburg FR, Zanarini MC, Kando J, Centorrino F. Clozapine and body mass change. Biol Psychiatry. 1998;43(7):520–524
  26. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry. 2001;62(Suppl 27):27–34[discussion 40-1]
  27. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60(6):358–363
  28. Scott CL. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol. 2003;92(1A):35i–42i
  29. Salzman S, Endicott J, Clayton R, Winkur G. Diagnostic evaluation after death (DEAD). Rockville (Md): National Institute of Mental Health, Neuroscience Research Branch; 1983;
  30. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I disorders–clinical version (SCID-CV). Washington (DC): American Psychiatric Press; 1997;
  31. National Institutes of Health . Calculate your body mass index. http://www.nhlbisupport.com/bmi/bmicalc.htm[accessed July 13, 2004]
  32. Halls SB. BMI calculator and body weight comparison. http://www.halls.md/bodymassindex/av.htm[accessed July 13, 2004]
  33. Chute D, Grove C, Rajasekhara B, Smialek JE. Schizophrenia and sudden death: a medical examiner case study. Am J Forensic Med Pathol. 1999;20(2):131–135
  34. Caldwell CB, Gottesman II. Schizophrenia—a high-risk factor for suicide: clues to risk reduction. Suicide Life Threat Behav. 1992;22(4):479–493
  35. Devlin MJ, Yanovski SZ, Wilson GT. Obesity: what mental health professionals need to know. Am J Psychiatry. 2000;157(6):854–866
  36. Lofgren P, Hoffstedt J, Ryden M, Thorne A, Holm C, Wahrenberg H, et al. Major gender differences in the lipolytic capacity of abdominal subcutaneous fat cells in obesity observed before and after long-term weight reduction. J Clin Endocrinol Metab. 2002;87(2):764–771
  37. Wang Y, Sullivan S, Trujillo M, Lee MJ, Schneider SH, Brolin RE, et al. Perilipin expression in human adipose tissues: effects of severe obesity, gender, and depot. Obes Res. 2003;11(8):930–936
  38. Lawson WB, Karson CN. Clinical correlates of body weight changes in schizophrenia. J Neuropsychiatry Clin Neurosci. 1994;6(2):187–188
  39. Lanzara D, Cosentino U, Lo Maglio AM, Lora A, Nicolo A, Rossini MS. Problems of patients with schizophrenic disorders and of their families. Epidemiol Psichiatr Soc. 1999;8(2):117–130
  40. Sommer R, Osmond H. The schizophrenic no-society revisited. Psychiatry. 1984;47(2):181–191
  41. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89–92
  42. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968–977
  43. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990;322(13):882–889
  44. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P. Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation. 1996;93(7):1372–1379
  45. Troiano RP, Frongillo EAJ, Sobal J, Levitsky DA. The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes Relat Metab Disord. 1996;20:63–65
  46. Bjorntorp P. Obesity and the risk of cardiovascular disease. Ann Clin Res. 1985;17(1):3–9
  47. Kortelainen ML. Association between cardiac pathology and fat tissue distribution in an autopsy series of men without premortem evidence of cardiovascular disease. Int J Obes Relat Metab Disord. 1996;20(3):245–252
  48. Kortelainen M-L, Särkioja T. Coronary atherosclerosis associated with body structure and obesity in 599 women aged between 15 and 50 y. Int J Obes Relat Metab Disord. 1999;23:838–844
  49. Sernyak MJ, Douglas DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561–566
  50. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry. 1968;124:978–982
  51. Lean MEJ, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 2003;26(5):1597–1605
  52. Wirshing DA. Adverse effects of atypical antipsychotics. J Clin Psychiatry. 2001;62:7–10

PII: S0010-440X(05)00033-7

doi: 10.1016/j.comppsych.2005.03.007

Comprehensive Psychiatry
Volume 46, Issue 6 , Pages 460-467 , November 2005

Article Tools